Literature DB >> 28964460

Contrast Agents for MR Imaging.

Ferenc Czeyda-Pommersheim1, Diego R Martin1, James R Costello1, Bobby Kalb2.   

Abstract

Contrast media are essential to the practice of MR imaging. An increasing variety of agents have been approved for clinical use, specific contrast agents can often be tailored to a specific clinical question. Compared with CT contrast media, MR imaging contrast is well tolerated with an excellent safety record and a low incidence of adverse events. In this article, we review the pharmacology, indications, and the common adverse events of the intravenous and oral MR contrast agents most commonly used in contemporary imaging practice, including gadolinium-based contrast, manganese and iron-based agents and the most common oral contrast agents.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contrast-enhanced MR imaging; Contrast-related adverse events; Gadolinium-based MR imaging contrast; Iron-based MR imaging contrast; Manganese-based MR imaging contrast; Radiographic contrast

Mesh:

Substances:

Year:  2017        PMID: 28964460     DOI: 10.1016/j.mric.2017.06.011

Source DB:  PubMed          Journal:  Magn Reson Imaging Clin N Am        ISSN: 1064-9689            Impact factor:   2.266


  3 in total

1.  Gadodiamide Induced Autophagy and Apoptosis in Human Keratinocytes.

Authors:  Yuh-Feng Tsai; Jai-Sing Yang; Yu-Jen Chiu; Chia-Wen Tsai; DA-Tian Bau; Wen-Shin Chang
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

2.  MultiHance as a contrast alternative for Gadovist allergic patients.

Authors:  Janna Malone; David Tiberi; Charles Frankish; Thanh Nguyen; John Sinclair; Shawn Malone
Journal:  Radiol Case Rep       Date:  2020-04-30

3.  Tumor-targeted Gd-doped mesoporous Fe3O4 nanoparticles for T1/T2 MR imaging guided synergistic cancer therapy.

Authors:  Shaohui Zheng; Shang Jin; Min Jiao; Wenjun Wang; Xiaoyu Zhou; Jie Xu; Yong Wang; Peipei Dou; Zhen Jin; Changyu Wu; Jingjing Li; Xinting Ge; Kai Xu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.